Retrospective Study
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2019; 11(8): 634-641
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study
Valeria Basso, David Orry, Jean Fraisse, Julie Vincent, Audrey Hennequin, Leila Bengrine, Francois Ghiringhelli
Valeria Basso, David Orry, Jean Fraisse, Department of Surgery, Centre Georges Francois Leclerc, Dijon 21000, France
Julie Vincent, Audrey Hennequin, Leila Bengrine, Francois Ghiringhelli, Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon 21000, France
Author contributions: Basso V collected clinical data; Orry D and Ghiringhelli F designed the study; Orry D, Fraisse J, Vincent J, Hennequin A and Ghiringhelli F treated patients includes in this study; Ghiringhelli F analyzed the data; Ghiringhelli F and Basso V wrote the manuscript; All authors have read and approve the final manuscript.
Informed consent statement: Written informed consent form was provided by family members of the patients.
Conflict-of-interest statement: All authors have no conflict of interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: François Ghiringhelli, MD, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr
Telephone: +33-380-732424 Fax: +33-380-737500
Received: March 18, 2019
Peer-review started: March 20, 2019
First decision: June 4, 2019
Revised: June 7, 2019
Accepted: June 20, 2019
Article in press: June 20, 2019
Published online: August 15, 2019
Abstract
BACKGROUND

Triplet chemotherapy, with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer (GC). An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results.

AIM

To determine safety and efficacy of TeFOX perioperative regimen.

METHODS

This monocentric retrospective study aims to test efficacy and safety of the perioperative TeFOX regimen given alone or in combination with trastuzumab in patients with localized GC. TeFOX consist in docetaxel (50 mg/m²) with oxaliplatin 85 mg/m² and and leucovorin (400 mg/m2) 5 FU bolus (400 mg/m2) on day 1, followed by continuous infusion of 5FU for 46 h (2400 mg/m2) every 2 wk.

RESULTS

Thirty-three consecutive patients were included in this retrospective study. Eighteen patients have a gastroesophageal junction cancer and 11 have a GC. Median follow-up of surviving patients was 32 mo. R0 resection was obtained in 30 (91) patients. Twelve patients (36) had a pathological complete response and 8 (24) patients a nearly complete pathological response. Median OS and PFS were not reached at data base lock. We have observed 6 metastatic relapses and 1 localized relapse. No relapse was observed in patients with pathological complete responses. The most common grade 3-4 adverse events were peripheral neuropathy (21) and asthenia (20).

CONCLUSION

TeFOX regimen could be safely administrated in perioperative treatment of localized GC. TeFOX and the FLOT regimen have comparable efficacy and safety profiles.

Keywords: Gastric cancer, Neoadjuvant chemotherapy, TeFOX, Retrospective study

Core tip: Triplet chemotherapy with docetaxel-5FU-oxaliplatin FLOT regimen recently became the standard perioperative treatment for localized gastric cancer. An adapted regimen called TeFOX was recently tested in metastatic setting and gave promising results. We provide here evidence based on our experience of the safety and efficacy of this regimen in patients treated in neoadjuvant setting.